Company insider dossier

Sanofi ADR insider intelligence

SNY filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.

Terminal chart Weekly report Factor intelligence Healthcare Drug Manufacturers - General Data API
72/100

Conviction accumulation

31/100 confidence
Exchange
NASDAQ
Sector
Healthcare
Industry
Drug Manufacturers - General
Latest evidence
6 Aug 2026

Investment committee read

Conviction accumulation

Priced common-share acquisitions carry more weighted evidence than disposals after freshness, role, size, and duplicate controls.

Research constructive setups

Evidence in favour

  • The latest qualifying evidence is fresh, dated 06 Aug 2026.

Decision risks

  • Reported purpose is unavailable in this feed, so even priced common-share transactions need filing context.
Conviction72Conviction accumulation
Confidence31Thin evidence
Named insiders1participating in the tape
Controlled events1directional common-share events
Acquisition value$5.1Mnormalized amount
Disposal value$0normalized amount

Price confirmation map

Weekly price with common-share events

Acquisitions and disposals are aligned to the nearest completed weekly bar.

53.7350.6247.5144.4041.29 Acquisition · 6 Aug 2026 · Not reportedAcquisition · 6 Aug 2026 · $5.1M
Feb 2025Aug 2026
Weekly closeCommon-share acquisitionCommon-share disposal

Market confirmation

Price and trend context

Latest close
43.46 USD
One-week move
+0.9%
Four-week move
-0.1%
Fair-value gap
-4.4%
Trend signal
Inactive
Relative strength
-15.9

Directional balance

Controlled event mix

100.0%acquisition
Acquisition events
1
Disposal events
0
Net value
$5.1M

Cadence

Twelve-week filing pressure

Volume shows attention. Controlled events determine direction.

025 May
001 Jun
008 Jun
015 Jun
022 Jun
029 Jun
006 Jul
013 Jul
020 Jul
027 Jul
303 Aug
010 Aug

Named participants

Insider conviction by person

SANOFI10% Owner721 events

Evidence quality

Security and transaction context

Common equity2
Equity compensation0
Options and derivatives0
Other securities1

Role architecture

Who is participating

Large holder3

Transaction evidence

Auditable SNY filing ledger

Showing 1 to 3 of 3.

SANOFI10% Owner
AcquisitionCommon equity
782855 sharesCommon Stock
Not reportedContext evidence
SANOFI10% Owner
DisposalOther securities
782855 sharesSeries C Preferred Stock
Not reportedContext evidence
SANOFI10% Owner
AcquisitionCommon equity
300000 sharesCommon Stock
$5.1MDirectional evidence

Reading the dossier

Direction and confidence are separate

Conviction

The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.

Confidence

Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.

Disposals

Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.

Price confirmation

The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context